T cell therapy with antivirals for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had hepatitis B surface antigen (HBsAg) in your blood for at least 6 months.
- You have a specific HLA type that matches the study treatment (HLA-A*02:01, A*11:01, or A*24:02).
- A liver test done in the last 6 months shows liver damage from hepatitis B but no severe scarring or cirrhosis.
- You do not have other causes of liver disease, such as autoimmune hepatitis or fatty liver disease.
- Your liver function is stable (no fluid in belly, no bleeding veins, and not in liver failure).
- You do not have HIV or any sign of liver cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.